Descrizione del progetto
Pancreas artificiali automatizzati per il trattamento del diabete di tipo 1
Il diabete di tipo 1 (DT1) è associato alla carenza di cellule che producono insulina nel pancreas e viene generalmente diagnosticato nei bambini e nei giovani. Nel corso della loro vita, i pazienti DT1 avranno bisogno di insulina esogena. Il progetto FORGETDIABETES, finanziato dall’UE, presenta un approccio radicalmente nuovo al trattamento del DT1, con lo sviluppo di un pancreas bionico invisibile immuno-ottimizzato, totalmente impiantabile e automatizzato. Questo pancreas bionico permetterà la somministrazione intraperitoneale di insulina per un controllo glicemico ottimale. Il team del progetto comprende esperti di alto livello in micro-nano meccatronica, biomateriali, endocrinologia, chirurgia e scienze comportamentali. Il pancreas bionico invisibile a lungo termine si baserà sul rilevamento fisiologico del glucosio e sul sistema di somministrazione dell’insulina, controllati da algoritmi adattativi personalizzati con capacità avanzate di autodiagnosi.
Obiettivo
FORGETDIABETES introduces a radically new approach to Type 1 Diabetes (T1D) treatment, by developing an immuno-optimized, fully-implantable, fully-automated, Bionic Invisible Pancreas (BIP). BIP targets physiological intraperitoneal hormone delivery, enabling an optimal glycemic control. T1D patient number is rising, projected at 63-94 million in 2045. T1D patients require exogenous insulin, resulting in an exorbitant number of actions: 100.000-500.000 in one patient’s life. BIP will free T1D subjects from therapeutic actions and from related psychological burden. BIP will become a life-condition (like wearing glasses), allowing T1D patients to live just as everybody else. An interdisciplinary team with top experts in micro-nano mechatronics, control engineering, biomaterials, endocrinology, surgery and behavioural sciences has been assembled to develop what was regarded as impossible for decades: a long-lasting system relying on a physiological glucose sensing and hormone delivery, orchestrated by personalized adaptive algorithms with advanced self-diagnostic capabilities. Pump refilling through a weekly oral recyclable drug pill will free T1D subjects from the burden of painful and awkward daily measurement and treatment actions.
Wireless power transfer and data transmission to cloud-based data management system round-up to a revolutionary treatment device for this incurable chronic disease. In this project, the key technologies enabling BIP will be developed. Furthermore, extensive in vivo preclinical experiments along with massive in silico testing will establish the proof-of-principle, paving the way to the ambitious first-in-human inpatient trial of BIP. This paradigm will revolutionize diabetes treatment and stimulate an innovation ecosystem including research bodies, SMEs, patient organizations, diabetes societies and clinicians. By investing in efforts like FORGETDIABETES, Europe will stand at the forefront of technological innovations for T1D treatment.
Campo scientifico
- medical and health sciencesclinical medicinesurgery
- medical and health sciencesclinical medicineendocrinologydiabetes
- engineering and technologymechanical engineeringmechatronics
- engineering and technologyindustrial biotechnologybiomaterials
- engineering and technologyelectrical engineering, electronic engineering, information engineeringelectronic engineeringcontrol engineering
Programma(i)
Invito a presentare proposte
Vedi altri progetti per questo bandoBando secondario
H2020-EIC-FETPROACT-2019
Meccanismo di finanziamento
RIA - Research and Innovation actionCoordinatore
35122 Padova
Italia